Transforming FVIII Product Classification: AUC and TTR as Game-Changing Metrics for Next-Generation Hemophilia A Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, has recently shared a very informative post on X:
‘‘Novel FVIII Classification: Scientific Framework for Next-Generation Haemophilia Treatment. Two pharmacokinetic metrics that can redefine how we classify Factor VIII products, presented by Professor Cedric Hermans at ISTH SSC FVIII/FIX session.
The Scientific Challenge
Traditional “standard” vs “extended” half-life classifications have proven inadequate for new generation FVIII products. Recent advances have led to improved ability to maintain FVIII levels within normal range.
New Classification Metrics
– Area Under the Curve (AUC) > 40%
Measures total drug exposure over time, providing comprehensive assessment of sustained FVIII activity rather than peak-focused measurements
– Time in Target Range (TTR) > 40%
Evaluates percentage of time patients maintain therapeutically effective FVIII levels, offering crucial insights into sustained haemostatic protection
Comparative Performance Data
– Standard Half-Life (SHL-FVIII): Baseline comparators (AUC ratio: 1, TTR ratio: 1)
– Extended Half-Life (EHL-FVIII): 4-5x AUC improvement, 2x TTR enhancement
– Ultra-Long/High Sustained Activity (UL/HSA-FVIII): 40x AUC improvement, 4x TTR boost
Products like efanesoctocog alfa demonstrate remarkable sustained activity, maintaining mean FVIII levels >40 IU/dL for 4 days with geometric mean half-life of 43.3 hours
Future Integration
Further validation can be warranted for integration into routine clinical evaluation and PK tools like WAPPS-Hemo, MyPKFit, and Florio. These platforms enable Bayesian forecasting of individual PK profiles for personalized treatment optimization.
As the field evolves toward normal hemostasis as the treatment goal, these metrics provide an important scientific basis for evaluating innovative therapies.”
Stay updated with Hemostasis Today.
-
Jul 11, 2025, 19:14ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
-
Jul 11, 2025, 16:48GPAS 2025: Shaping the Future of Bleeding Disorder Care
-
Jul 10, 2025, 11:23HTRS Thanks CSL Behring for Its Ongoing Commitment to Research Support
-
Jul 9, 2025, 14:11Join Dr. Bethany Samuelson Bannow for a Virtual Event on Hemostasis and Cancer
-
Jul 9, 2025, 13:59Late-Breaking Insights from ISTH 2025: Rurioctocog Alfa Pegol in PUPs with Hemophilia A
-
Jul 12, 2025, 16:21Richard Buka։ Evolution’s Imprint on Blood, Natural Selection Shaping Today’s Hematologic Disorders
-
Jul 12, 2025, 15:337 Tesla MRI Sheds Light on END Mechanisms in Symptomatic MCA Stenosis
-
Jul 12, 2025, 15:221 in 100: Subclavian Steal Syndrome Revealed by LVO Stroke in Case with Persistent Trigeminal Artery
-
Jul 11, 2025, 18:50ICAS Not a Factor: Post-EVT Intensive BP Control within 24 hrs Worsens Outcomes
-
Jul 11, 2025, 17:57Need for Recanalization Strategies Reinforced in P1 and P2: PCA Stroke Poor Outcomes
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 6, 2025, 21:00From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs
-
Jul 6, 2025, 15:02Patients as Experts: EHC Calls for Early Involvement in HTA Systems
-
Jul 6, 2025, 14:56Missed ISTH 2025? Congress Daily Has You Covered
-
Jul 6, 2025, 11:48Japan's Youth Engagement in Hemophilia Care: Where Even the Doctors Get It – HABIT Summit 2025